12 de June de 2019

Brazilian regulatory agency (ANVISA) inaugurates discussion on cannabis for medicinal and scientific purposes

ANVISA’s Board of Directors approved the proposal to open two Public Consultations to regulate:

(i) the cultivation of the cannabis spp. for medical and scientific purposes; and

(ii) a specific procedure for registration and monitoring of medicines based on Cannabis spp., its derivatives, and synthetic analogs.

For further information, click below to access our full newsletter.

Last related news

20 de October de 2025

Last month, Brazil took a major step toward regulating the digital environment for children and adolescents with the enactment of the ECA … Brazil enacts the ECA Digital: a landmark law for children’s rights in the Digital Age

17 de October de 2025

Brazil, despite being among the top 20 countries in terms of the number of clinical trials, contributes less than 2% of global … New Rules for Clinical Research: Federal Government Bets on Regulation to Boost Innovation and Investment

Kasznar Leonardos

13 de October de 2025

The 2025 Nobel Prize in Economic Sciences recognized Joel Mokyr, Philippe Aghion, and Peter Howitt for their theoretical contributions on how innovation … 2025 Nobel Prize in Economics: innovation as an engine of transformation